Clinical Trials on Surgical Wound Infection in Chile

Total 410 results

Novartis Pharmaceuticals

Completed

Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis (FUTURE5)

Psoriatic Arthritis

United States, United Kingdom, India, Austria, Denmark, Netherlands, Spain, Germany, Thailand, Israel, Argentina, Greece, Philippines, Latvia, Italy, Guatemala, Russian Federation, Hungary, Ireland, Vietnam, Czechia, Canada, Sweden, M... and more
AstraZeneca

Completed

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS)

Myocardial Infarction | Stroke | Atherothrombosis | Cardiovascular Death

Sweden, United States, Australia, Brazil, Bulgaria, Czech Republic, France, Italy, Korea, Republic of, Peru, Poland, Russian Federation, South Africa, Spain, Turkey, United Kingdom, Germany, Philippines, China, Hungary, Romania, U... and more
AbbVie

Active, not recruiting

A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) (SELECT - PsA 2)

Psoriatic Arthritis

United States, Belgium, Brazil, Canada, Chile, Czechia, France, Greece, Hungary, Italy, Japan, Netherlands, New Zealand, Portugal, Puerto Rico, Spain, United Kingdom
Sanofi

Completed

Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy (TAO)

Acute Coronary Syndrome

Austria, Korea, Republic of, Brazil, Belarus, India, Latvia, Belgium, Canada, Israel, Portugal, Germany, United States, Argentina, Australia, Bulgaria, Chile, Colombia, Croatia, Czech Republic, Egypt, Estonia, France, Greece, Hong Kong, Hungar... and more
Bristol-Myers Squibb

Active, not recruiting

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

Psoriatic Arthritis

Russian Federation, United States, Argentina, Australia, Brazil, Bulgaria, Chile, China, Colombia, Czechia, Finland, France, Hungary, Ireland, Italy, Mexico, Poland, Romania, Spain, Taiwan, United Kingdom
Cogentus Pharmaceuticals

Terminated

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1) (COGENT-1)

Myocardial Infarction | Coronary Artery Disease | Acute Coronary Syndrome | Percutaneous Coronary Intervention

United States, France, Canada, Australia, Poland, Germany, Italy, Mexico, Romania, Slovakia, Hungary, Czech Republic, Chile, Bulgaria, Puerto Rico, Ukraine
AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

Psoriatic Arthritis

United States, Argentina, Australia, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Estonia, Finland, Germany, Greece, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico and more
Johnson & Johnson Pharmaceutical Research & Development...
Bayer

Completed

An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome

Myocardial Infarction | Myocardial Ischemia | Acute Coronary Syndrome | Unstable Angina

United States, France, Poland, Ukraine, United Kingdom, China, Belgium, Germany, Spain, Argentina, Chile, Colombia, Israel, Mexico, Portugal, Bulgaria, India, Malaysia, Romania, Russian Federation, Serbia, Turkey, Korea, Republic of, ... and more
AbbVie

Active, not recruiting

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) (SELECT - PsA 1)

Psoriatic Arthritis

United States, Argentina, Australia, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic... and more
BioNTech SE

Recruiting

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT)

Recurrent Head and Neck Cancer | Unresectable Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Cancer

Germany, United States, France, United Kingdom, Korea, Republic of, Spain, Poland, Belgium, Brazil, Taiwan, Italy, Canada, Czechia, Australia, Turkey, Mexico, Chile, Argentina, Austria, Hungary, Portugal, Sweden

Clinical Trials on Surgical Wound Infection in Chile

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations